An Observational Study of Evidence-Based Therapies in Older Patients with Heart Failure with Reduced Ejection Fraction: Insights from a Dedicated Heart Failure Clinic

一项针对射血分数降低型心力衰竭老年患者的循证疗法观察性研究:来自专科心力衰竭诊所的见解

阅读:1

Abstract

Background/Objectives: Despite significant advances in the management of heart failure with reduced ejection fraction (HFrEF), data concerning older patients remain limited. The purpose of this study was to evaluate the implementation of guideline-directed medical therapy (GDMT) in older patients with HFrEF along with cardiac events and variation in clinical and echocardiographic parameters during follow-up in a heart failure (HF) clinic. Methods: We conducted a retrospective observational analysis of patients with HFrEF aged ≥ 80 years who attended an HF clinic between March 2022 and February 2023. The primary outcome was a composite of the first episode of worsening HF or cardiovascular death. All-cause death was also recorded. Results: We included 110 patients (30.9% females; mean age 82.9 years). After a median follow-up of 25.5 months, left ventricular ejection fraction (LVEF) improved (mean difference 12.5% (p < 0.001)). New York Heart Association class improved in 37% of patients, and N-terminal pro-B-type natriuretic peptide levels decreased (3091 (158-53354) to 1802 (145-19509), p < 0.001). The primary outcome occurred in 34 patients (30.9%). Patients without the primary outcome were more likely to receive sodium-glucose co-transporter-2 inhibitors (SGLT2i) (23.5% versus 67.1%, p < 0.001) and angiotensin receptor-neprilysin inhibitors, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers (67.6% versus 84.2%, p < 0.05). These patients also received a greater number of GDMT medications (2 (0-4) versus 3 (1-4), p < 0.01) and demonstrated a higher LVEF at the last visit (41.2 ± 10.2% versus 47.1 ± 9.4%, p < 0.05). Survival analysis demonstrated a significant association between LVEF recovery (hazard ratio (HR) 0.35, p < 0.01), treatment with two or more GDMT medications (HR 0.29, p < 0.01), vasodilator use (HR 0.36, p < 0.01), and SGLT2i prescription (HR 0.17, p < 0.001) and a reduced risk of the primary endpoint. Conclusions: The optimization of HF treatment is achievable in older patients and may be associated with a reduction in cardiac events.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。